Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.

CONTEXT Cushing's disease as a result of a pituitary macroadenoma is an uncommon cause of Cushing's syndrome, and reports in the published literature are few and of limited size. OBJECTIVE Our objective was to establish the clinical and biochemical characteristics of macroadenomas associated with Cushing's disease compared with a large cohort of microadenomas and to assess their response to therapy. DESIGN We conducted a retrospective case-records study for the years 1964-2001. SETTING The study occurred at a tertiary referral hospital center. PATIENTS Patients had Cushing's disease presenting with a pituitary macroadenoma, in comparison with a large group of microadenoma patients. INTERVENTIONS Interventions included therapy with surgery and radiotherapy. MAIN OUTCOME MEASURES Outcome measures included basal and dynamically responsive plasma ACTH and cortisol levels and response to treatment. RESULTS We identified 18 patients with Cushing's disease secondary to a macroadenoma; basal 0900 h plasma ACTH was 135.8 +/- 32.5 and 45.0 +/- 4.3 ng/liter (mean +/- SEM), respectively, in macroadenomas and microadenomas (P = 0.013). Mean 0900 h serum cortisol was significantly increased in the macroadenomas (27.5 +/- 3.0 microg/dl, 759.6 +/- 82.6 nmol/liter, vs. 22.6 +/- 0.6 microg/dl, 624.7 +/- 16.4 nmol/liter) (P = 0.021). Testing with high-dose dexamethasone showed less suppression in the macroadenomas (57.6 +/- 8.7% vs. 74.4 +/- 2.1%; P = 0.02) and an attenuated ACTH response to CRH. For all biochemical variables there was considerable overlap between the two groups. Few patients with macroadenomas were cured by surgery. CONCLUSIONS Pituitary macroadenomas causing Cushing's disease have biochemical features largely distinct from patients harboring microadenomas but represent one end of a continuum.

[1]  S. Czirják,et al.  Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  A B Atkinson,et al.  Diagnosis and complications of Cushing's syndrome: a consensus statement. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  S. Chew,et al.  Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. , 2003, The Journal of clinical endocrinology and metabolism.

[4]  E. Menis,et al.  Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. , 2003, European journal of endocrinology.

[5]  A. Cukiert,et al.  Glucocorticoid receptor gene polymorphisms in ACTH‐secreting pituitary tumours , 2002, Clinical endocrinology.

[6]  M. Korbonits,et al.  Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  P. Kendall‐Taylor,et al.  Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? , 2001, Clinical endocrinology.

[8]  D. Lüdecke,et al.  Cushing's disease: a surgical view; This Publication is dedicated to our professor emeritus Dr. med. Rudolf Kautzky , 2001, Journal of Neuro-Oncology.

[9]  C Hagen,et al.  Incidence and late prognosis of cushing's syndrome: a population-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  F. Mangili,et al.  Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. , 2000, The American journal of pathology.

[11]  C. Invitti,et al.  Diagnosis and management of Cushing's syndrome : Results of an Italian multicentre study , 1999 .

[12]  A. Grossman,et al.  The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. , 1998, Endocrine reviews.

[13]  D. Schoenfeld,et al.  Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[14]  M. Buysschaert,et al.  Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. , 1998, European journal of endocrinology.

[15]  G. Tindall,et al.  Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[16]  T. Yoshimoto,et al.  Clinico‐pathological study of Cushing's disease with large pituitary adenoma , 1997, Clinical endocrinology.

[17]  H. Raff,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Effectiveness Versus Efficacy: The Limited Value in Clinical Practice of High Dose Dexamethasone Suppression Testing in the Differential Diagnosis , 2022 .

[18]  R. Fahlbusch,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Glucocorticoid Receptor Gene Isoforms in Corticotropin-Secreting Tumors* , 2022 .

[19]  R. Magallón,et al.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. , 1997, The New England journal of medicine.

[20]  M. Boscaro,et al.  Risk factors and long-term outcome in pituitary-dependent Cushing's disease. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  D. Ray,et al.  Impaired processing of proopiomelanocortin in corticotroph macroadenomas. , 1996, The Journal of clinical endocrinology and metabolism.

[22]  M. Buchfelder,et al.  Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. , 1995, The Journal of clinical endocrinology and metabolism.

[23]  R. Ross,et al.  Diagnosis and selective cure of Cushing's disease during pregnancy by transsphenoidal surgery. , 1995, European journal of endocrinology.

[24]  A. Grossman,et al.  The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. , 1995, The Journal of clinical endocrinology and metabolism.

[25]  E. Ogata,et al.  Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. , 1994, The Journal of clinical endocrinology and metabolism.

[26]  D. Lowe,et al.  Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successfuI treatment , 1993, Clinical endocrinology.

[27]  E. Hedley‐Whyte,et al.  Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. , 1992, The Journal of clinical endocrinology and metabolism.

[28]  X. Bertagna,et al.  Monoclonality of corticotroph macroadenomas in Cushing's disease. , 1992, The Journal of clinical endocrinology and metabolism.

[29]  M. Littley,et al.  LONG‐TERM FOLLOW‐UP OF LOW‐DOSE EXTERNAL PITUITARY IRRADIATION FOR CUSHING'S DISEASE , 1990, Clinical endocrinology.

[30]  N. Watts,et al.  Cushing's disease: results of transsphenoidal microsurgery with emphasis on surgical failures. , 1990, Journal of neurosurgery.

[31]  J. Tyrrell,et al.  Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. , 1988, Annals of internal medicine.

[32]  Tetsuo Kato,et al.  Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. , 1987, Neurosurgery.

[33]  J. Thomson,et al.  TRANSSPHENOIDAL MICROSURGERY FOR CUSHING'S DISEASE , 1984, Clinical endocrinology.

[34]  J. Tyrrell,et al.  Transsphenoidal microsurgical management of Cushing's disease. Report of 100 cases. , 1983, Journal of neurosurgery.

[35]  D. Cook,et al.  PRO‐OPIOCORTIN RELATED PEPTIDES IN HUMAN PITUITARY AND ECTOPIC ACTH SECRETING TUMOURS , 1983, Clinical endocrinology.